Guardant Health Yönetim

Yönetim kriter kontrolleri 4/4

Guardant Health CEO'su Helmy Eltoukhy, Jan2013 tarihinde atandı, in görev süresi 9.83 yıldır. in toplam yıllık tazminatı $ 13.67K olup, şirket hissesi ve opsiyonları dahil olmak üzere 0.01% maaş ve 100% ikramiyelerden oluşmaktadır. şirketin hisselerinin 2.27% ine doğrudan sahiptir ve bu hisseler € 114.55M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.5 yıl ve 4.1 yıldır.

Anahtar bilgiler

Helmy Eltoukhy

İcra Kurulu Başkanı

US$13.7k

Toplam tazminat

CEO maaş yüzdesi	0.007%
CEO görev süresi	9.8yrs
CEO sahipliği	2.3%
Yönetim ortalama görev süresi	2.5yrs
Yönetim Kurulu ortalama görev süresi	4.1yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Helmy Eltoukhy'un ücretlendirmesi Guardant Health'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2022	n/a	n/a	-US$606m
Jun 30 2022	n/a	n/a	-US$551m
Mar 31 2022	n/a	n/a	-US$419m
Dec 31 2021	US$14k	US$1	-US$406m
Sep 30 2021	n/a	n/a	-US$409m
Jun 30 2021	n/a	n/a	-US$379m
Mar 31 2021	n/a	n/a	-US$336m
Dec 31 2020	US$114m	US$210k	-US$254m
Sep 30 2020	n/a	n/a	-US$185m
Jun 30 2020	n/a	n/a	-US$120m
Mar 31 2020	n/a	n/a	-US$77m
Dec 31 2019	US$915k	US$500k	-US$76m
Sep 30 2019	n/a	n/a	-US$76m
Jun 30 2019	n/a	n/a	-US$87m
Mar 31 2019	n/a	n/a	-US$97m
Dec 31 2018	US$818k	US$480k	-US$85m
Sep 30 2018	n/a	n/a	-US$75m
Jun 30 2018	n/a	n/a	-US$84m
Mar 31 2018	n/a	n/a	-US$83m
Dec 31 2017	US$4m	US$460k	-US$89m

Tazminat ve Piyasa: Helmy 'nin toplam tazminatı ($USD 13.67K ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 3.58M ).

Tazminat ve Kazançlar: Helmy 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Helmy Eltoukhy (43 yo)

9.8yrs

Görev süresi

US$13,665

Tazminat

Dr. Helmy Eltoukhy, Ph D., is Equity Partner and Advisor of Transform VC. Dr. Eltoukhy has been the Chairman of the Board of Directors of Guardant Health, Inc. since August 05, 2021.He has been the Co-Chi...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Helmy Eltoukhy	Co-Founder	9.8yrs	US$13.67k	2.27% € 114.5m
AmirAli Talasaz	Co-CEO & Director	1.3yrs	US$13.27k	2.27% € 114.7m
Michael Bell	Chief Financial Officer	1.8yrs	US$6.46m	0.0020% € 101.6k
John Saia	Chief Legal Officer	2.5yrs	US$1.71m	0.013% € 674.6k
Craig Eagle	Chief Medical Officer	1.5yrs	US$6.46m	0.0024% € 119.8k
Christopher Freeman	Chief Commercial Officer of Oncology Business	1.4yrs	US$5.44m	0.0031% € 157.7k
Andy Ament	Senior Vice President of Operations	2.7yrs	Veri yok	Veri yok
Darya Chudova	Senior Vice President of Technology	no data	Veri yok	Veri yok
Kumud Kalia	Chief Information Officer	2.8yrs	Veri yok	0.023% € 1.1m
Jennifer Higgins	Vice President of Public Affairs	no data	Veri yok	Veri yok
Amelia Merrill	Senior Vice President of People	no data	Veri yok	0.022% € 1.1m
Michael Wiley	Head of Corporate Affairs	2.5yrs	US$1.75m	0.00091% € 46.0k

2.5yrs

Ortalama Görev Süresi

48yo

Ortalama Yaş

Deneyimli Yönetim: 5GH 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.5 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Helmy Eltoukhy	Co-Founder	9.8yrs	US$13.67k	2.27% € 114.5m
AmirAli Talasaz	Co-CEO & Director	9.8yrs	US$13.27k	2.27% € 114.7m
Myrtle Potter	Independent Director	1.1yrs	US$729.74k	0.00080% € 40.4k
Ian T. Clark	Lead Independent Director	5.8yrs	US$470.13k	0.0022% € 108.7k
Samir Kaul	Independent Director	8.6yrs	US$425.13k	0.011% € 533.7k
Steve Krognes	Director	less than a year	Veri yok	Veri yok
Vijaya Gadde	Independent Director	2.4yrs	US$425.13k	0.0064% € 321.4k
Meghan Joyce	Independent Director	1.3yrs	US$721.34k	0.00097% € 49.0k

4.1yrs

Ortalama Görev Süresi

47.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 5GH 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.1 yıldır).

Guardant Health Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Guardant Health, Inc. Appoints Roberto Mignone. as Class I Director

Guardant Health, Inc. Announces the Appointment of Dr. Manuel Hidalgo Medina to Board of Directors

Guardant Health, Inc., Annual General Meeting, Jun 12, 2024

Guardant Health, Inc. Announces Executive Changes

Guardant Health, Inc. Announces Management Changes

Senior Vice President of People recently sold €212k worth of stock

Recent updates

Guardant Health, Inc. Revises Revenue Guidance for the Year 2024

Guardant Health, Inc. Appoints Roberto Mignone. as Class I Director

Guardant Health, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Guardant Health, Inc. has filed a Follow-on Equity Offering in the amount of $400 million.

Guardant Health, Inc. Raises Earnings Guidance for the Full Year of 2024

Guardant Health, Inc.'s FDA-Appoints Shield™? Blood Test Now Commercially Available in U.S. as a Primary Screening Option for Colorectal Cancer

Guardant Health, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Guardant Health, Inc. Introduces Major Smart Liquid Biopsy Upgrade to Market-Leading Guardant360® Test, Further Extending Its Best-In-Class Performance

Guardant Health, Inc. Announces the Appointment of Dr. Manuel Hidalgo Medina to Board of Directors

Guardant Health Introduces New Guardant360 Tissuenext Test with Nearly 500 Biomarkers to Identify More Treatment Options for Patients with Advanced Cancer

Guardant Health, Inc. Announces FDA Advisory Committee Panel Strongly Recommends Approval of Shield™ Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening Option

Guardant Health, Inc. Raises Financial Guidance for the Full Year of 2024

Guardant Health, Inc., Annual General Meeting, Jun 12, 2024

Guardant Health, Inc. to Report Q1, 2024 Results on May 09, 2024

Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting

Guardant Health, Inc. Announces Results from the ECLIPSE Study Showing the Effectiveness of Its Shield Blood Test for Detecting Colorectal Cancer

Guardant Health, Inc. Provides Earnings Guidance for the Year 2024

Guardant Health, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Guardant Health, Inc. Announces Executive Changes

Guardant Health, Inc. Announces Tentative Date of FDA Advisory Panel Review of Shield(TM) Blood Test

Guardant Health, Inc. to Appeal Federal District Court Verdict

Guardant Health, Inc. Provides Revenue Guidance for Full Year 2023

Guardant Health, Inc. Announces Initial Results from the PEGASUS Trial

Guardant Health, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Guardant Health, Inc. Receives Coverage for Guardant Reveal from Geisinger Health Plan

Guardant Health, Inc. Receives Regulatory Approval in Japan for Guardant360®? CDx as Companion Diagnostic to ENHERTU®? for Treatment of Non-Small Cell Lung Cancer Patients with HER2 Mutations

Guardant Health, Inc. Revises Revenue Guidance for the Full Year 2023

Guardant Resolves Pending Litigation with Illumina and Enters into New Agreement to Advance Long-Term Commercial Partnership and Cancer Research

Guardant Health, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Guardant Health, Inc. Announces Reimbursement Approval of Guardant360 CDx Liquid Biopsy Test in Japan

Guardant Health, Inc.(NasdaqGS:GH) dropped from Russell 1000 Dynamic Index

Guardant Health, Inc. has completed a Follow-on Equity Offering in the amount of $350 million.

Guardant Health, Inc. Revises Revenue Guidance for the Full Year 2023

Guardant Health, Inc. Announces Management Changes

Guardant Health, Inc. Initiates New Study to Examine the Impact of Shield Blood Test to Increase Screening Compliance for Colorectal Cancer

Guardant Health, Inc. Receives Coverage from UnitedHealthcare for Guardant360® CDx Blood Test as Companion Diagnostic in Advanced Lung and Breast Cancer

Guardant Health, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Guardant Health Introduces Guardant Galaxytm Suite of Advanced Ai Analytics to Enhance Its Portfolio of Cancer Tests and Accelerate Biomarker Discovery

Guardant Health, Inc. Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for Menarini Group’S ORSERDU for Treatment of Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer

Guardant Health and the Royal Marsden NHS Foundation Trust Partner on Highly Anticipated TRACC Part C Trial to Use Guardant Reveal(Tm) Blood Test to Help Guide Treatment Decisions in Colorectal Cancer

Guardant Health, Inc. to Showcase New Data at ASCO GI 2023 Demonstrating Utility of its Blood Tests for Patients with Gastrointestinal Cancers

Guardant Health, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Guardant Health, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Guardant Health, Inc. and Susan G. Komen(R) Partner to Develop Clinical Studies to Identify Early-Stage Breast Cancer Patients Who May Benefit from Additional Monitoring or Therapy

Guardant Health Announces Positive Results from Pivotal ECLIPSE Study Evaluating A Blood Test for the Detection of Colorectal Cancer

Guardant Health, Inc. Provides Earnings Guidance for the Full Year 2022

Guardant Health, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Guardant Health Introduces GuardantINFINITY Smart Liquid Biopsy for Research Use to Help Bring New Cancer Therapies to Patients Sooner

Guardant Health, Inc. to Showcase New Data At ESMO 2022 Demonstrating Utility of Its Portfolio of Blood Tests for Advanced-Stage Cancer Patients

Senior Vice President of People recently sold €212k worth of stock

Guardant Health, Inc. Receives FDA Approval for Guardant360® Cdx as Companion Diagnostic for Daiichi Sankyo and Astrazeneca’S Enhertu® for Treatment of Nsclc Patients with Activating Her2 Mutations

Second quarter 2022 earnings released: US$2.25 loss per share (vs US$0.96 loss in 2Q 2021)

Guardant Health, Inc. Provides Earnings Guidance for the Full Year 2022

Guardant Health, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Guardant Health, Inc. Appoints Steve E. Krognes as Class III Director, Effective June 30, 2022

Guardant Health, Inc. Presents New Data Showing Blood Test Accuracy in Detecting Colorectal Cancer in First-Of-Its Kind Prospective Study At Digestive Disease Week 2022

First quarter 2022 earnings released: US$1.21 loss per share (vs US$1.09 loss in 1Q 2021)

Guardant Health, Inc. Provides Revenue Guidance for the Year 2022

Guardant Health, Inc. Announces Shield™ Blood Test Available in US to Detect Early Signs of Colorectal Cancer in Average-Risk Adults

Guardant Health, Inc. to Report Q1, 2022 Results on May 05, 2022

Guardant Health, Inc. Presents New Data Showing Blood Test Highly Accurate in Detecting Multiple Cancers at the American Association for Cancer Research Annual Meeting

Guardant Health, Inc. Announces That Stanley Meresman Will Not Stand for Re-Election to the Company’s Board of Directors

Guardant Health, Inc. Provides Revenue Guidance for the Year 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Guardant Health, Inc. to Report Q4, 2021 Results on Feb 23, 2022

Guardant Health to Present Data Highlighting the Clinical Utility of Its Liquid Biopsy Tests in Gastrointestinal Cancers at ASCO GI Cancers Symposium

Guardant Health, Inc. Enrolls First Patient in SHIELD LUNG Study to Evaluate Accuracy of Its Blood Test to Detect Lung Cancer in High-Risk Adults

Guardant Health Reaches Target Enrollment of 12,750 Patients in Eclipse Pivotal Study for Its Lunar-2 Blood Test to Detect Colorectal Cancer

Co-Founder recently bought €8.9m worth of stock